Anbio biotechnology class a ordinary sharesNNNN.US Overview

US StockHealthcare

(No presentation for NNNN)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

NNNN Overall Performance

NNNN AI Analysis & Strategy

NNNN Recent Performance

-1.58%

Anbio biotechnology class a ordinary shares

0.81%

Avg of Sector

-1.14%

S&P500

NNNN PowerScanner

NNNN Key Information

NNNN Valuation Metrics

NNNN Earnings Table

NNNN Profile

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.